New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
10:51 EDTEW, MDTEdwards up after court limits sale of Medtronic's CoreValve in U.S.
Shares of cardiovascular technology company Edwards Lifesciences (EW) are rising today after a U.S. district court granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the U.S. Shares of Medtronic, meanwhile, are falling following the news. WHAT'S NEW: On April 12, Edwards said a U.S. district court in Delaware granted a preliminary injunction, to go into effect in seven days, limiting the sale of Medtronic's CoreValue system in the U.S. In addition, the court ordered Medtronic and Edwards to enter into immediate talks to agree on a mechanism that will enable physicians at facilities currently trained on CoreValve to make a clinical judgment as to which device to implant, free from the limitations of the injunction. Medtronic responded on April 13 by saying that the ruling has no impact on the sale or marketing of CoreValue outside of the U.S. or the use of CoreValue in the current U.S. clinical trials. Medtronic is appealing the court's injunction and intends to ask the Federal Circuit Court of Appeals to prevent it from going into effect until it determines if the injunction was properly issued. ANALYST REACTION: JPMorgan upgraded Edwards Lifesciences to Neutral from Underweight following the news and raised its price target for shares to $78 from $60. JPMorgan also downgraded Medtronic to Neutral and lowered its price target on that stock to $64 from $69. Another firm, CRT Capital, also upgraded Edwards Lifesciences in response to the news. CRT Capital analyst Shagun Chadha feels that the court decision to grant a preliminary injunction against MDT’s CoreValve focuses the market balance in favor of Edwards and took the stock up to Buy from Fair Value with a price target of $87. Canaccord Genuity analyst Jason Mills said that Edwards achieved a "surprising" and noteworthy win in the courts. Mills noted, however, that he still foresees Edwards to cash in via other forms of equitable relief in lieu of a final injunction. The firm is maintaining its 12-month price target of $84 on Edwards Lifesciences shares. PRICE ACTION: During morning trading, shares of Edwards Lifesciences were up $10.01 or 13.72% to $82.98. Shares of Medtronic fell $1.28 or 2.16% to $57.92.
News For EW;MDT From The Last 14 Days
Check below for free stories on EW;MDT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
17:12 EDTEWOn The Fly: Closing Wrap
Subscribe for More Information
08:16 EDTEWEdwards Lifesciences price target raised to $103 from $96 at Canaccord
Subscribe for More Information
July 29, 2014
18:35 EDTEWOn The Fly: After Hours Movers
Subscribe for More Information
16:18 EDTEWEdwards Lifesciences sees Q3 EPS 66c-72c, consensus 74c
Subscribe for More Information
16:17 EDTEWEdwards Lifesciences raises 2014 EPS outlook to $3.24-$3.34, consensus $3.19
Subscribe for More Information
16:16 EDTEWEdwards Lifesciences reports Q2 EPS 88c, consensus 77c
Reports Q2 revenue $575.1M, consensus $544.3M.
15:53 EDTEWNotable companies reporting after market close
Subscribe for More Information
July 28, 2014
12:46 EDTMDTMedtronic receives FDA approval for PRESTIGE cervical disc system
Subscribe for More Information
11:07 EDTEW, MDTLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
06:52 EDTMDTFormer official says Obama could limit inversion deals, NY Times reports
President Obama could limit tax inversion deals on his own authority, said Stephen Shay, former deputy assistant Treasury secretary for international tax affairs in the Obama administration, according to The New York Times. A 1969 law gives the president the ability to restrict inversion deals, said Shay, who also worked in the Reagan administration, the newspaper stated. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Alletgan (AGN). Reference Link
July 25, 2014
06:30 EDTMDTObama calls on Congress to end inversion deals, NY Times reports
Subscribe for More Information
July 24, 2014
08:19 EDTMDTLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
July 22, 2014
07:57 EDTEWHouse Energy & Commerce Committee to hold a hearing
The Subcommittee on Health holds a hearing entitled, "21st Century Cures: Examining Barriers to Ongoing Evidence Development and Communication" with CEO Mussallem at Edwards Lifesciences on July 22 at 3 pm. Webcast Link
July 21, 2014
08:16 EDTMDTDeutsche Bank analysts hold an analyst/industry conference call
Subscribe for More Information
July 18, 2014
12:51 EDTMDTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use